Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer.

Journal of gynecologic oncology·2024

Same author

Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy.

Medical oncology (Northwood, London, England)·2022

Same author

Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.

Medical oncology (Northwood, London, England)·2022

Same author

Inhibitory role of a smart nano-trifattyglyceride of <i>Moringa oleifera</i> root in epithelial ovarian cancer, through attenuation of FSHR - c-Myc axis.

Journal of traditional and complementary medicine·2021

Same author

Immune checkpoints, their control by immunotherapy and ovarian cancer.

Contemporary oncology (Poznan, Poland)·2017

Same author

PARP inhibitors and more.

Journal of the Turkish German Gynecological Association·2015

Search research articles

Related Experiment Video

Updated: Feb 23, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Immune Checkpoint Blockers and Ovarian Cancer.

Chinmoy K Bose¹

¹Department of Gynaecological Oncology and Clinical Trial, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India.

Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology

|September 14, 2017

Summary

Cancer immunotherapy faced challenges translating to humans but advanced with the discovery of cytotoxic T-lymphocyte antigen-4 (CTLA4) immune checkpoints. Targeting CTLA4 revitalized tumor immunology, offering new hope for treating refractory cancers.

Keywords:

Immune checkpoint T-cell ovarian cancer

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Related Experiment Videos

Last Updated: Feb 23, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Area of Science:

Immunology
Oncology

Background:

Cancer immunotherapy has shown promise in preclinical models but faced significant challenges in human translation.
By the 1990s, many researchers had abandoned cancer immunotherapy due to these difficulties.

Purpose of the Study:

To highlight the pivotal discovery of T-cell suppression by cytotoxic T-lymphocyte antigen-4 (CTLA4).
To underscore the impact of anti-CTLA4 antibodies in initiating a new era of tumor immunology.
To discuss the role of immune checkpoints in managing challenging cancers.

Main Methods:

Identification of T-cell suppression mediated by the CTLA4 molecule.
Development of antibody-based therapies targeting CTLA4.
Exploration of immune checkpoint inhibitors for cancer treatment.

Main Results:

The discovery of CTLA4's role led to the development of antibody therapies that enhance T-cell activity.
Immune checkpoint manipulation has emerged as a crucial strategy for controlling malignant tumors.
These approaches show promise in managing recurrent and refractory cancers, including melanoma, renal cell carcinoma, and ovarian cancer.

Conclusions:

Immune checkpoint inhibition represents a significant advancement in cancer treatment, particularly for difficult-to-treat malignancies.
Despite ongoing challenges, the field is rapidly progressing, offering new therapeutic avenues and hope for patients.
Continuous updates are essential for understanding and applying these evolving immunotherapeutic strategies.